Phospholipid transfer protein activity and incident type 2 diabetes mellitus

Clinica Chimica Acta

Volumn 439, Issue , 2014, Pages 38-41

  Abbasi, Ali ^a,b   Dallinga Thie, Geesje M ^c   Dullaart, Robin P F ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; Phospholipid transfer protein activity; Risk factor; Type 2 diabetes mellitus

Indexed keywords

PHOSPHOLIPID TRANSFER PROTEINS; PLTP PROTEIN, HUMAN;

BLOOD; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; METABOLISM; MIDDLE AGED;

DIABETES MELLITUS, TYPE 2; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 84908147302     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.09.035     Document Type: Article

References (12)

1. Tzotzas T., Desrumaux C., Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes Rev 2009, 10:403-411.
2. Dullaart R.P.F., van Tol A., Dallinga-Thie G.M. Phospholipid transfer protein, an emerging cardiometabolic risk marker: is it time to intervene?. Atherosclerosis 2013, 228:38-41.
3. Vergeer M., Boekholdt S.M., Sandhu M.S., et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010, 122:470-477.
4. Moerland M., Samyn H., van Gent T., et al. Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:1277-1282.
5. Schlitt A., Liu J., Yan D., Mondragon-Escorpizo M., Norin A.J., Jiang X.C. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim Biophys Acta 2005, 1733:187-191.
6. Borggreve S.E., Hillege H.L., Dallinga-Thie G.M., et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 2007, 28:1012-1018.
7. Abbasi A., Corpeleijn E., Gansevoort R.T., et al. Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study. J Clin Endocrinol Metab 2013, 98:E1352-E1359.
8. Balkau B., Lange C., Fezeu L., et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2008, 31:2056-2061.
9. Nguyen A.T., Mandard S., Dray C., et al. Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes 2014, 63:471-482.
10. Lakomy D., Rebe C., Sberna A.L., et al. Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. Arterioscler Thromb Vasc Biol 2009, 29:1923-1929.
11. Li N., van der Sijde M.R., Study L.C., et al. Pleiotropic effects of lipid genes on plasma glucose, HbA1c and HOMA-IR levels. Diabetes 2014, 63:3149-3158.
12. Abbasi A., Corpeleijn E., Meijer E., et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 2012, 55. [1963-197].